Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | LPAR3 | Q9UBY5 | 5/20 | 0.45 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.45 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | THRA | P10827 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14760427 | 0.94 | LPAR3 (0.53) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL4267782 | 0.92 | LPAR3 (0.57) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL17355671 | 0.83 | CYP3A4 (0.52) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL2238085 | 0.80 | CYP3A4 (0.48) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL2485153 | 0.80 | CYP3A4 (0.48) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL4267682 | 0.80 | CYP3A4 (0.48) | CYP3A4TSHRALDH1A1AKR1B1 | |
| SCHEMBL15951693 | 0.80 | CYP3A4 (0.48) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL28916156 | 0.79 | CYP3A4 (0.47) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL2354042 | 0.79 | CYP3A4 (0.47) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL17878594 | 0.79 | CYP3A4 (0.47) | CYP3A4LPAR3LPAR1LPAR2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233889-B1 | ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS | SHANGHAI MICURX PHARMACEUTICAL CO LTD (CN) | 2022-07-06 | — | — | EP | disclosed |
| CN-107257803-B | Polymyxin antibacterial agents for the treatment of bacterial infections | 上海盟科药业股份有限公司 | 2021-02-05 | — | — | CN | disclosed |
| EP-3233889-A2 | ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS | Micurx Pharmaceuticals, Inc. (US) | 2017-10-25 | — | — | EP | disclosed |
| CN-107257803-A | Polymyxins antiseptic for treating bacterium infection | 盟科医药技术公司（开曼群岛） | 2017-10-17 | — | — | CN | disclosed |
| US-9771394-B2 | Antimicrobial polymyxins for treatment of bacterial infections | MICURX PHARMACEUTICALS, INC. (KY) | 2017-09-26 | — | — | US | disclosed |
| US-9771394-B2 | Antimicrobial polymyxins for treatment of bacterial infections | MICURX PHARMACEUTICALS, INC. (KY) | 2017-09-26 | — | — | US | disclosed |
| US-9771394-B2 | Antimicrobial polymyxins for treatment of bacterial infections | MICURX PHARMACEUTICALS, INC. (KY) | 2017-09-26 | — | — | US | disclosed |
| US-20160185823-A1 | ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS | MICURX PHARMACEUTICALS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20160185823-A1 | ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS | MICURX PHARMACEUTICALS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20160185823-A1 | ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS | MICURX PHARMACEUTICALS, INC. | 2016-06-30 | — | — | US | disclosed |
| WO-2016100578-A2 | ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS | MICURX PHARMACEUTICALS, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016100578-A2 | ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS | MICURX PHARMACEUTICALS, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| US-20120022024-A1 | ANTI-BACTERIAL COMPOSITIONS AND METHODS INCLUDING TARGETING VIRULENCE FACTORS OF STAPHYLOCOCCUS AUREUS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2012-01-26 | — | — | US | disclosed |
| EP-0690890-A1 | PHOSPHORUS-CONTAINING FLAME RETARDANTS | COURTAULDS PLC (GB) | 1996-01-10 | — | — | EP | disclosed |
| WO-1994021724-A1 | PHOSPHORUS-CONTAINING FLAME RETARDANTS | COURTAULDS PLC (GB) | 1994-09-29 | — | — | WO | disclosed |
| US-5210259-A | PROCESS FOR THE OXIDATION OF DIALKYL ESTERS OF 2-HYDROXY-ETHYLPHOSPHONIC ACID | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022024-A1 | ANTI-BACTERIAL COMPOSITIONS AND METHODS INCLUDING TARGETING VIRULENCE FACTORS OF STAPHYLOCOCCUS AUREUS | CUTA, MMP8, CLPP | CYP3A4 4878/4885LPAR3 1768/4885LPAR1 1764/4885 |
| US-20160185823-A1 | ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS | VIP, AQP1, PEF1 | CYP3A4 3756/4885LPAR3 2783/4885LPAR1 3457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.